Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash's TriActiv distal protection system for saphenous vein graft interventions is associated with significantly more in-hospital hemorrhagic/vascular events than controls in the firm's PRIDE trial
You may also be interested in...
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation
Kensey Nash Reviewing TriActiv Distal Protection Marketing Options
Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says